Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-3C5 · 1 trial · 1 indication
AEs include serious AEs (SAEs). AEs do not distinguish whether the events are treatment-emergent. A summary of serious and other non-serious AEs, regardless of causality, is presented in the Reported Adverse Event module.
A DLT was defined as any adverse event (National Cancer Institute \[NCI\]-Common Terminology Criteria for Adverse Events \[CTCAE\], Version 4.0) considered by the investigator to be definitely, probably, or possibly related to IMC-3C5, that occurred during the DLT Assessment Period (weeks 1 through 6) as follows: * Any Grade 3 or 4 hematologic toxicity * Any Grade 3 or 4 nonhematologic toxicity (excluding fatigue or anorexia lasting \<7 days, or Grade 3 nausea and/or vomiting that persisted for \<2 days following appropriate supportive care intervention)
| Arm | Type | Description |
|---|---|---|
| IMC-3C5 | EXPERIMENTAL | Participants receiving IMC-3C5 intravenously |
| Name | Type | Description |
|---|---|---|
| IMC-3C5 | BIOLOGICAL | Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week |
Inclusion Criteria: 1. Participant has histologic or cytologic confirmation of cancer 2. Participant has an advanced solid tumor that is refractory to standard therapy or for which no standard therapy is available 3. Participant has measurable or nonmeasurable disease according to Response Evaluati...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
IMC-3C5 is an investigational monoclonal antibody being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed for use in oncology, specifically for patients with advanced solid tumors.
IMC-3C5 targets VEGFR-3, a receptor involved in the growth of lymphatic vessels. By binding to VEGFR-3, the antibody aims to interfere with signaling pathways that may contribute to tumor growth and spread. This mechanism is being explored in the context of advanced solid tumors.
IMC-3C5 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
IMC-3C5 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, tolerability, and potential efficacy in patients with advanced solid tumors.
IMC-3C5 has been studied in a Phase 1 clinical trial with the identifier NCT01288989. This trial, titled 'A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors,' was conducted in the United States and enrolled 44 participants. The trial has been completed.
IMC-3C5 is an anti-VEGFR-3 monoclonal antibody, as described in the clinical trial title. The drug is referred to by its code name IMC-3C5, and its mechanism involves targeting the VEGFR-3 receptor. No other alternative names have been established in the available information.